Skip to content
Search

Latest Stories

Amgen sues Novartis in US court to block generic osteoporosis, bone cancer drugs

Pb Staff writer
By Pb Staff writerMay 03, 2023
Pb Staff writer
See Full Bio

Amgen Inc sued Novartis AG's Sandoz in a federal court in the United States on Monday (May 1), accusing Sandoz's proposed versions of its multibillion-dollar bone-strengthening drugs Prolia and Xgeva of infringing several patents.

Amgen asked the New Jersey court to block Sandoz's biosimilars of the drugs until its patents expire. One of the patents named in the complaint does not expire until 2037.

Sandoz declined to comment on the lawsuit on Tuesday. Novartis, which is also named in the complaint, is preparing to spin Sandoz off into a standalone company later this year.

Amgen's Prolia is used to treat osteoporosis. Xgeva, with the same active ingredient denosumab, treats bone cancer and prevents fractures in bone-cancer patients.

Amgen said the proposed biosimilars infringe 21 patents covering Prolia and Xgeva.

proliaamgensandozxgevanovartis

Related News

Cargo plane unloading pharmaceuticals at US airport amid tariff concerns and stockpiling
News

Pharma imports to US surged in March as drugmakers look to avoid tariffs

WW International logo with bold bankruptcy notice and confident recovery statement

US diet company WeightWatchers files for bankruptcy

Scottish community pharmacist working in high street pharmacy with supportive environment
News

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK
News

Aspire acquires UK distribution rights from Tetris

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Pharmacist declining participation in assisted dying under new UK legislation

It could take another four years for assisted dying to become law

Pic credit: iStock

Pharmacists to have choice to opt-out of assisted dying process

Pharmacists will not be forced to be a part in assisted dying cases with the MP leading the campaign expected to made amendments to the bill which is currently going through parliamentary process.

Kim Leadbeater, the MP behind the Terminally Ill Adults (End of Life) Bill, will say that “no person is under any duty to participate in the provision of assistance”.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less
© Copyright 2025 Garavi Gujarat Publications Ltd & Garavi Gujarat Publications USA Inc